Italian cohort of

nivolumab Expanded Access Programme EAP preliminary data from a realworld population Lucio Crinò et al Intervista a Angelo Delmonte Background Nivolumab is the first checkpoint inhibitor approved for the treatment of squamous non small cell lung cancer SqNSCLC to show a survival benefit in a randomised phase III trial The experience of patients and physicians in routine clinical practice is often different from those in a controlled clinical trial setting The purpose of this analysis is to evaluate nivolumab use in real world setting

Embed this Presentation

Download Notice

Download Presentation The PPT/PDF document "Italian cohort of" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.